Clarion vs Hims & Hers

Side-by-side comparison of AI visibility scores, market position, and capabilities

Hims & Hers leads in AI visibility (86 vs 39)
Clarion logo

Clarion

EmergingHealthcare

General

AI healthcare communication platform handling patient scheduling, billing, and prescriptions; backed by Accel and YC quadrupling revenue while serving a $5B health insurance provider.

AI VisibilityBeta
Overall Score
D39
Category Rank
#440 of 596
AI Consensus
76%
Trend
stable
Per Platform
ChatGPT
44
Perplexity
41
Gemini
38

About

Clarion is an AI healthcare communication platform that deploys intelligent voice and messaging agents to handle high-volume patient interactions for clinics and health systems — automating appointment scheduling, billing inquiries, prescription refill requests, and patient follow-up communications that currently consume significant front-office staff time. Founded in 2024 and backed by Accel, Y Combinator, and Sequoia Scout with $5.4-5.8 million raised, Clarion has quadrupled revenue in recent months while serving tens of thousands of patients monthly across virtual care companies, health systems, and a $5 billion health insurance provider.\n\nClarion's AI agents handle patient-initiated contacts across phone, SMS, and web channels — scheduling appointments without hold times, answering billing questions, processing routine prescription refill requests, and sending proactive outreach for appointment reminders and care gap closures. The agents integrate with EHR systems (Epic, athenahealth) and practice management systems to access patient records and schedule availability, enabling context-aware conversations that feel more like interacting with an informed staff member than a phone tree.\n\nIn 2025, Clarion competes in the healthcare AI communication and patient engagement market with Nuance (Microsoft Dragon Ambient and DAX), Relatient (patient scheduling and communication), and Klara (patient messaging platform) for healthcare front-office automation. The healthcare front office represents one of the most labor-intensive and patient-satisfaction-critical functions in a medical practice — phone hold times and scheduling difficulties are top complaints from patients. Accel and Sequoia Scout backing at the seed stage reflects conviction about the market size and Clarion's early commercial traction. The 2025 strategy focuses on growing within health systems and virtual care companies, deepening EHR integrations, and expanding the AI agent capabilities to handle more complex patient interaction types beyond routine scheduling.

Full profile
Hims & Hers logo

Hims & Hers

EmergingHealthcare

Telehealth Pharmacy

Consumer telehealth platform with Q3 2025 revenue of $599M (+49% YoY); 2.47M subscribers; 2025 guidance $2.3-2.4B; acquiring ZAVA for European expansion; GLP-1 weight loss, hair, and sexual health treatments shipped directly to subscribers.

AI VisibilityBeta
Overall Score
A86
Category Rank
#8 of 596
AI Consensus
79%
Trend
stable
Per Platform
ChatGPT
88
Perplexity
92
Gemini
83

About

Hims & Hers is a consumer telehealth and pharmacy platform founded in 2017 in San Francisco by Andrew Dudum, built on the mission of making high-quality healthcare affordable and stigma-free for conditions that people historically avoided treating due to embarrassment, cost, or access barriers. The platform's core technology combines a direct-to-consumer digital health interface with an integrated pharmacy network, enabling patients to complete asynchronous or synchronous consultations with licensed clinicians and receive prescription treatments — including compounded medications — delivered directly to their homes.\n\nHims & Hers serves patients across sexual health, hair loss, mental health, dermatology, and weight management. The company's expansion into GLP-1 compounded weight loss medications has been a significant growth catalyst, capitalizing on surging consumer demand for semaglutide and tirzepatide alternatives during periods of branded drug shortages. With 2.47 million subscribers and a subscription-centric business model, the platform generates predictable recurring revenue from patients on ongoing treatment protocols. The company's 2025 acquisition of ZAVA expands its addressable market into European telehealth markets.\n\nHims & Hers reported Q3 revenue of $599 million, a 49% year-over-year increase, and issued full-year 2025 guidance of $2.3 to $2.4 billion — a scale that makes it one of the largest consumer telehealth companies in the world. The company's ability to compound subscriber growth with expanding treatment categories and international expansion through ZAVA provides multiple vectors for continued revenue acceleration. As healthcare consumerization intensifies and patients increasingly manage chronic conditions through digital-first platforms, Hims & Hers' brand recognition, integrated pharmacy infrastructure, and subscription model give it a durable position in consumer health.

Full profile

AI Visibility Head-to-Head

39
Overall Score
86
#440
Category Rank
#8
76
AI Consensus
79
stable
Trend
stable
44
ChatGPT
88
41
Perplexity
92
38
Gemini
83
36
Claude
90
34
Grok
89

Key Details

Category
General
Telehealth Pharmacy
Tier
Emerging
Emerging
Entity Type
brand
brand

Capabilities & Ecosystem

Capabilities

Only Hims & Hers
Telehealth Pharmacy

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.